Cited by 1,394Antiplatelet Therapy and Cardiovascular DiseasesInflammatory mediators and NSAID effectsPlatelet Disorders and Treatments

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin

Open access

Catella-Lawson, Francesca, Reilly, Muredach P., Kapoor, Shiv C., Cucchiara, Andrew J., DeMarco, Susan, Tournier, Barbara, Vyas, Sachin N., FitzGerald, Garret A.·2001·New England Journal of Medicine

DOI 10.1056/nejmoa003199

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Patients with arthritis and vascular disease may receive both low-dose aspirin and other nonsteroidal antiinflammatory drugs. We therefore investigated potential interactions between aspirin and commonly prescribed arthritis therapies METHODS: We administered the following combinations of drugs for six days: aspirin (81 mg every morning) two hours before ibuprofen (400 mg every morning) and the same medications in the reverse order; aspirin two hours before acetaminophen (1000 mg every morning) and the same medications in the reverse order; aspirin two hours before the cyclooxygenase-2 inhibitor rofecoxib (25 mg every morning) and the same medications in the reverse order; enteric-coated aspirin two hours before ibuprofen (400 mg three times a day); and enteric-coated aspirin two hours before delayed-release diclofenac (75 mg twice daily) RESULTS: Serum thromboxane B(2) levels (an index of cyclooxygenase-1 activity in platelets) and platelet aggregation were maximally inhibited 24 hours after the administration of aspirin on day 6 in the subjects who took aspirin before a single daily dose of any other drug, as well as in those who took rofecoxib or acetaminophen before taking aspirin. In contrast, inhibition of serum thromboxane B(2) formation and platelet aggregation by aspirin was blocked when a single daily dose of ibuprofen was given before aspirin, as well as when multiple daily doses of ibuprofen were given. The concomitant administration of rofecoxib, acetaminophen, or diclofenac did not affect the pharmacodynamics of aspirin CONCLUSIONS: The concomitant administration of ibuprofen but not rofecoxib, acetaminophen, or diclofenac antagonizes the irreversible platelet inhibition induced by aspirin. Treatment with ibuprofen in patients with increased cardiovascular risk may limit the cardioprotective effects of aspirin.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa003199

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Bombardier, C., Laine, L., Reicin, A. S., Shapiro, D., Burgos‐Vargas, R., Davis, B. R., Day, R. O., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,014
Final Report on the Aspirin Component of the Ongoing Physicians' Health Study
Steering Committee of the Physicians' Health Study Research Group (1989) · New England Journal of Medicine · doi:10.1056/nejm198907203210301 · Cited by 2,267
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,572
Self-citation
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S. C., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,304
Self-citation
The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
Picot, D., Loll, P. J., & Garavito, R. M. (1994) · Nature · doi:10.1038/367243a0 · Cited by 1,270
Platelet-Active Drugs
Patrono, C., Coller, B. S., Dalen, J. E., Gerald, G. A. F., Fuster, V., Gent, M., Hirsh, J., & Roth, G. J. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.39s · Cited by 961
Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects
Patrignani, P., Filabozzi, P., & Patrono, C. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110576 · Cited by 931
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11475-1 · Cited by 829
Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
Luong, C., Miller, A. B., Barnett, J. W., Chow, J., Ramesha, C. S., & Browner, M. F. (1996) · Nature Structural Biology · doi:10.1038/nsb1196-927 · Cited by 620
Effects of Specific Inhibition of Cyclooxygenase-2 on Sodium Balance, Hemodynamics, and Vasoactive Eicosanoids
Catella-Lawson, F., McAdam, B. F., Morrison, B. W., Kapoor, S. C., Kujubu, D. A., Antes, L. M., Lasseter, K. C., Quan, H., Gertz, B. J., & FitzGerald, G. A. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38195-9 · Cited by 596
Self-citation

Flagged first, then by citations

Show all 44 references

Research works printed but not linked: 7

Singh G, 1999, J Rheumatol, 26, 18
Patrignani P, 1999, J Physiol Pharmacol, 50, 661
Pathmakanthan S, 1998, Ir Med J, 91, 58
Patrignani P, 1994, J Pharmacol Exp Ther, 271, 1705
Sciulli MG, Patrignani P, Seta F, et al. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells in vitro. In: Proceedings of the 11th International Conference on Advances in Prostaglandin and Leukotriene Research: Basic Science and New Clinical Applications, Florence, Italy, June 4–8, 2000:38. abstract.
Reilly IAG, 1987, Blood, 69, 180, 10.1182/blood.V69.1.180.180 · DOI
Catella-Lawson F, 1999, J Pharmacol Exp Ther, 289, 735

Sorted by citations

Items 201–300 of 1,000

Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements
Sweeny, J. M., Gorog, D. A., & Fuster, V. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.10 · Cited by 96
Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor
Dallob, A. L., Hawkey, C. J., Greenberg, H. E., Wight, N. J., Schepper, P. D., Waldman, S. A., Wong, P., DeTora, L. M., Gertz, B. J., Agrawal, N. G. B., et al. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003043006003 · Cited by 96
Use of Nonsteroidal Anti-Inflammatory Drugs in Patients With Cardiovascular Disease
Amer, M., Bead, V. R., Bathon, J. M., Blumenthal, R. S., & Edwards, D. N. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181ce1521 · Cited by 94
Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study
Rahme, E., & Nedjar, H. (2007) · Rheumatology · doi:10.1093/rheumatology/kel428 · Cited by 92
Cardiovascular hazard and non-steroidal anti-inflammatory drugs
Wong, D., Wang, M., Cheng, Y., & FitzGerald, G. A. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.02.001 · Cited by 95
Self-citation
Nabumetone
Hedner, T., Samulesson, O., hrborg, P. W., Wadenvik, H., Ung, K., & Ekbom, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00004 · Cited by 94
NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project
Petrick, J. L., Sahasrabuddhe, V. V., Chan, A. T., Alavanja, M. C. R., Freeman, L. E. B., Buring, J. E., Chen, J., Chong, D. Q., Freedman, N. D., Fuchs, C. S., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0126 · Cited by 93
An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
Tannenbaum, H., Bombardier, C., Davis, P. J., & Russell, A. S. (2006) · PubMed · Cited by 92
The Biochemical Selectivity of Novel COX-2 Inhibitors in Whole Blood Assays of COX-isozyme Activity
Tacconelli, S., Capone, M. L., Sciulli, M. G., Ricciotti, E., & Patrignani, P. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125001335 · Cited by 91
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Angiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J., Granger, C. B., Mauri, L., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004395 · Cited by 90
Determinants of the interindividual variability in response to antiplatelet drugs
Rocca, B., & Patrono, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01380.x · Cited by 89
Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets
Saxena, A., Balaramnavar, V. M., Hohlfeld, T., & Saxena, A. K. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.032 · Cited by 88
Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years
Ziesenitz, V. C., Welzel, T., van Dyk, M., Saur, P., Gorenflo, M., & van den Anker, J. N. (2022) · Pediatric Drugs · doi:10.1007/s40272-022-00514-1 · Cited by 97
Opioids for Chronic Pain: New Evidence, New Strategies, Safe Prescribing
de León-Casasola, O. A. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.11.011 · Cited by 88
Pain management today—what have we learned?
Langford, R. (2006) · Clinical Rheumatology · doi:10.1007/s10067-006-0311-5 · Cited by 87
Towards an Effective and Safe Treatment of Inflammatory Pain: A Delphi-Guided Expert Consensus
Varrassi, G., Alon, E., Bagnasco, M., Lanata, L., Mayoral, V., Paladini, A., Pergolizzi, J. V., Perrot, S., Scarpignato, C., & Tölle, T. R. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01053-x · Cited by 93
Antiplatelet resistance in stroke
Topçuoğlu, M. A., Arsava, E. M., & Ay, H. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.203 · Cited by 86
Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events
Hankey, G. J., & Eikelboom, J. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70038-7 · Cited by 87
Consensus Development Conference on the Use of Nonsteroidal Anti-Inflammatory Agents, Including Cyclooxygenase-2 Enzyme Inhibitors and Aspirin
Wilcox, C. M., Allison, J. J., Benzuly, K. H., Borum, M. L., Cryer, B., Großer, T., Hunt, R. H., Ladabaum, U., Lanas, Á., & Paulus, H. E. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.04.010 · Cited by 87
An Alkyne–Aspirin Chemical Reporter for the Detection of Aspirin-Dependent Protein Modification in Living Cells
Bateman, L. A., Zaro, B. W., Miller, S. M., & Pratt, M. R. (2013) · Journal of the American Chemical Society · doi:10.1021/ja408322b · Cited by 88
Time to stroke: A Western Trauma Association multicenter study of blunt cerebrovascular injuries
Burlew, C. C., Sumislawski, J. J., Behnfield, C., McNutt, M. K., McCarthy, J., Sharpe, J. P., Croce, M. A., Bala, M., Kashuk, J. L., Spalding, M. C., et al. (2018) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001989 · Cited by 84
Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity
McEvoy, L., Carr, D. F., & Pirmohamed, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.684162 · Cited by 84
Tetranor PGDM, an Abundant Urinary Metabolite Reflects Biosynthesis of Prostaglandin D2 in Mice and Humans
Song, W., Wang, M., Ricciotti, E., Fries, S., Yu, Y., Großer, T., Reilly, M. P., Lawson, J. A., & FitzGerald, G. A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706839200 · Cited by 83
Self-citation
Differentiation of Cyclooxygenase 1- and 2–Derived Prostanoids in Mouse Kidney and Aorta
Qi, Z., Cai, H., Morrow, J. D., & Breyer, M. D. (2006) · Hypertension · doi:10.1161/01.hyp.0000231934.67549.b7 · Cited by 84
Evidence-Based Recommendations for Short- and Long-Term Management of Uninvestigated Dyspepsia in Primary Care: An Update of the Canadian Dyspepsia Working Group (CanDys) Clinical Management Tool
van Zanten, S. J. V., Bradette, M., Chiba, N., Armstrong, D., Barkun, A. N., Flook, N. W., Thomson, A. B. R., & Bursey, F. R. (2005) · Canadian Journal of Gastroenterology · doi:10.1155/2005/674607 · Cited by 84
Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited
Walker, C., & Biasucci, L. M. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1412799 · Cited by 83
Coxibs and Heart Disease
Zarraga, I. G. E., & Schwarz, E. R. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.003 · Cited by 82
The Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
BENNETT, J. S., Daugherty, A., Herrington, D. M., Greenland, P., Roberts, H. R., & Taubert, K. A. (2005) · Circulation · doi:10.1161/01.cir.0000160005.90598.41 · Cited by 84
Cyclooxygenase-2 Inhibitors
Gajraj, N. M. (2003) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000061461.55712.c5 · Cited by 83
A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis
Fendrick, A. M., & Greenberg, B. P. (2009) · Osteopathic Medicine and Primary Care · doi:10.1186/1750-4732-3-1 · Cited by 84
Non-steroidal anti-inflammatory drugs: an overview
Jahnavi, K., Reddy, P. P., Bakshi, V., & Boggula, N. (2019) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v9i1-s.2287 · Cited by 82
Human Pharmacology of Naproxen Sodium
Capone, M. L., Tacconelli, S., Sciulli, M. G., Anzellotti, P., Francesco, L. D., Merciaro, G., Gregorio, P. D., & Patrignani, P. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.122283 · Cited by 82
Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor
Patrignani, P., Capone, M. L., & Tacconelli, S. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.2.265 · Cited by 82
Cyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke
Haag, M. D. M. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.11.1219 · Cited by 83
Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
Pham, T., Gossec, L., Constantin, A., Pavy, S., Bruckert, É., Cantagrel, A. G., Combe, B. G., Flipo, R., Goupille, P., Loët, X. L., et al. (2006) · Joint Bone Spine · doi:10.1016/j.jbspin.2006.01.014 · Cited by 81
Therapeutic approaches in arterial thrombosis
Phillips, D. R., Conley, P. B., Sinha, U., & André, P. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01418.x · Cited by 81
Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease
Bavry, A. A., Khaliq, A., Gong, Y., Handberg, E. M., Cooper‐DeHoff, R. M., & Pepine, C. J. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.02.025 · Cited by 80
Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent
Zimmermann, N., Gams, E., & Hohlfeld, T. (2008) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2008.03.023 · Cited by 85
Safety of Ibuprofen in Patients With COVID-19
Sodhi, M., & Etminan, M. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.03.040 · Cited by 81
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial
Leonardi, S., Mahaffey, K. W., White, H. D., Gibson, C. M., Stone, G. W., Steg, P. G., Hamm, C. W., Price, M. J., Todd, M., Dietrich, M., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.02.018 · Cited by 79
Parsing an enigma: the pharmacodynamics of aspirin resistance
FitzGerald, G. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12560-3 · Cited by 80
Self-citation
Guidelines on the management of stable angina pectoris
Skalidis, E. I., & Vardas, P. E. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl257 · Cited by 80
Novel Applications of NSAIDs: Insight and Future Perspectives in Cardiovascular, Neurodegenerative, Diabetes and Cancer Disease Therapy
Kaduševičius, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126637 · Cited by 85
Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction
Patel, T. N., & Goldberg, K. C. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.8.852 · Cited by 79
Assessment of Bleeding Risk of Interventional Techniques: A Best Evidence Synthesis of Practice Patterns and Perioperative Management of Anticoagulant and Antithrombotic Therapy
Manchikanti, L. (2013) · Pain Physician · doi:10.36076/ppj.2013/16/se216 · Cited by 78
Synthesis and Chemical and Biological Comparison of Nitroxyl- and Nitric Oxide-Releasing Diazeniumdiolate-Based Aspirin Derivatives
Basudhar, D., Bharadwaj, G., Cheng, R. Y. S., Jain, S., Shi, S., Heinecke, J. L., Holland, R. J., Ridnour, L. A., Caceres, V., Spadari-Bratfisch, R. C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400196q · Cited by 78
High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs – pharmacological mechanisms and clinical relevance
Saxena, A., Schrör, K., & Hohlfeld, T. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-07-0532 · Cited by 78
Primer: managing NSAID-induced ulcer complications—balancing gastrointestinal and cardiovascular risks
Chan, F. K. L. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0610 · Cited by 78
The coxibs and traditional nonsteroidal anti-inflammatory drugs: A current perspective on cardiovascular risks
Cairns, J. A. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70732-8 · Cited by 78
Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population
Rodríguez, L. A. G., & González‐Pérez, A. (2005) · BMC Medicine · doi:10.1186/1741-7015-3-17 · Cited by 76
The risk of cardiovascular thrombotic events with selective cyclooxygenase‐2 inhibitors
Strand, V., & Hochberg, M. C. (2002) · Arthritis Care & Research · doi:10.1002/art.10560 · Cited by 76
Pharmacoepidemiology of non-steroidal anti-inflammatory drugs
Moore, N. D., Duong, M., Gülmez, S. E., Blin, P., & Droz‐Perroteau, C. (2018) · Therapies · doi:10.1016/j.therap.2018.11.002 · Cited by 78
Ibuprofen: from invention to an OTC therapeutic mainstay
Rainsford, K. D. (2012) · International Journal of Clinical Practice · doi:10.1111/ijcp.12055 · Cited by 75
Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors
Rostom, A. (2009) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s4334 · Cited by 74
Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs
Li, X., Fries, S., Li, R., Lawson, J. A., PROPERT, K. J., Diamond, S. L., Blair, I. A., FitzGerald, G. A., & Großer, T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406997111 · Cited by 74
Self-citation
Comorbid Conditions in the AMICA Study Patients: Effects on the Quality of Life and Drug Prescriptions by General Practitioners and Specialists
Caporali, R. F., Cimmino, M. A., Sarzi‐Puttini, P., Scarpa, R., Parazzini, F., Zaninelli, A., Ciocci, A., & Montecucco, C. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.02.004 · Cited by 74
Aspirin Resistance
Tantry, U. S., Mahla, E., & Gurbel, P. A. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.05.001 · Cited by 75
Bioavailability of diclofenac potassium at low doses
Hinz, B., Chevts, J., Renner, B., Wuttke, H., Rau, T., Schmidt, A., Szelenyi, I., Brune, K., & Werner, U. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02226.x · Cited by 73
Resistance to antiplatelet drugs: current status and future research
Tantry, U. S., Bliden, K. P., & Gurbel, P. A. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.12.2027 · Cited by 72
50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams
Halford, G. M., Lordkipanidzé, M., & Watson, S. P. (2011) · Platelets · doi:10.3109/09537104.2011.632032 · Cited by 72
Targeting Outpatient Drug Safety
Herwaarden, M. F. W., Kramers, C., Sturkenboom, M., van den Bemt, P. M. L. A., & Smet, P. A. G. M. D. (2012) · Drug Safety · doi:10.2165/11596000-000000000-00000 · Cited by 75
Disease modification and cardiovascular risk reduction: two sides of the same coin?
Hall, F. C., & Dalbeth, N. (2005) · Rheumatology · doi:10.1093/rheumatology/kei012 · Cited by 71
New Directions in Antiplatelet Therapy
Ferreiro, J. L., & Angiolillo, D. J. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.966176 · Cited by 72
Aspirin resistance
Szczeklik, A., Musiał, J., Undas, A., & Sanak, M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01372.x · Cited by 71
Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition
Yu, Y., Cheng, Y., Fan, J., Chen, X., Klein–Szanto, A. J., FitzGerald, G. A., & Funk, C. D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23683 · Cited by 70
Self-citation
Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)
Combe, B. G., Swergold, G. D., McLay, J., McCarthy, T., Zerbini, C. A. F., Emery, P., Connors, L., Kaur, A., Curtis, S., Laine, L., et al. (2009) · Rheumatology · doi:10.1093/rheumatology/kep005 · Cited by 72
Current Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction
Fischer, L. M., Schlienger, R. G., Matter, C. M., Jick, H., & Meier, C. R. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.25.4.503.61021 · Cited by 70
The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding
Konstantinopoulos, P. A., & Lehmann, D. F. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005278202 · Cited by 70
Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
Jourdi, G., Lordkipanidzé, M., Philippe, A., Bachelot‐Loza, C., & Gaussem, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313079 · Cited by 76
Effects of Ibuprofen on the Magnitude and Duration of Aspirin's Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis
Gengo, F. M., Rubin, L. E., Robson, M. J., Rainka, M. M., Gengo, M. F., Mager, D. E., & Bates, V. E. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007310379 · Cited by 69
The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers
Schuijt, M., Huntjens‐Fleuren, H., Metz, M. D., & Vollaard, E. J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00243.x · Cited by 69
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Study Program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis
Cannon, C. P., Curtis, S., Bolognese, J. A., & Laine, L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.05.024 · Cited by 68
Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis
White, W. B., Strand, V., Roberts, R., & Whelton, A. (2004) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000127360.23508.04 · Cited by 69
Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention
Broussalis, E., Killer‐Oberpfalzer, M., McCoy, M. R., Harrer, A., Trinka, E., & Kraus, J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.11.005 · Cited by 71
Why Is COVID-19 More Severe in Patients With Diabetes? The Role of Angiotensin-Converting Enzyme 2, Endothelial Dysfunction and the Immunoinflammatory System
Roberts, J., Pritchard, A. L., Treweeke, A. T., Rossi, A. G., Brace, N., Cahill, P. A., MacRury, S. M., Wei, J., & Megson, I. L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.629933 · Cited by 68
Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications
Pieringer, H., & Pichler, M. (2010) · QJM · doi:10.1093/qjmed/hcq203 · Cited by 69
Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry
Li, N., Hu, H., & Hjemdahl, P. (2003) · Thrombosis Research · doi:10.1016/j.thromres.2003.08.026 · Cited by 67
An Experimental and Computational Study of the Loading and Release of Aspirin from Zeolite HY
Datt, A., Fields, D., & Larsen, S. C. (2012) · The Journal of Physical Chemistry C · doi:10.1021/jp3067266 · Cited by 67
The evolution of the Helsinki frostbite management protocol
Lindford, A. J., Valtonen, J., Hult, M., Kavola, H., Lappalainen, K., Lassila, R., Aho, P., & Vuola, J. (2017) · Burns · doi:10.1016/j.burns.2017.04.016 · Cited by 67
Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?
Clark, D. W. J., Layton, D., & Shakir, S. (2004) · Drug Safety · doi:10.2165/00002018-200427070-00002 · Cited by 67
Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study
Meek, I., Vonkeman, H. E., Kasemier, J., Movig, K. L. L., & van de Laar, M. A. F. J. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1370-y · Cited by 65
Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019
DGRh, Kiltz, U., DEGAM, DWG, DVMB, DOG, DRG, DGMM, DGPMR/DGRW, Deutschland, P., et al. (2019) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-019-0670-3 · Cited by 65
Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study
de Abajo, F. J., Gil, M., García-Poza, P., Bryant, V., Oliva, B., Timoner, J., & García‐Rodríguez, L. A. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3617 · Cited by 66
Variability in the Responsiveness to Low-Dose Aspirin: Pharmacological and Disease-Related Mechanisms
Rocca, B., & Petrucci, G. (2012) · Thrombosis · doi:10.1155/2012/376721 · Cited by 65
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: Recommendations to minimize the functional consequences
Anzellotti, P., Capone, M. L., Jeyam, A., Tacconelli, S., Bruno, A., Tontodonati, P., Francesco, L. D., Grossi, L., Renda, G., Merciaro, G., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.30175 · Cited by 65
Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients
Schwartz, K. A., Schwartz, D. E., Barber, K. R., Reeves, M. J., & Franco, A. C. D. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-46 · Cited by 65
Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs
Chaiamnuay, S., Allison, J. J., & Curtis, J. R. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050519 · Cited by 73
Diclofenac Potassium 12.5mg Tablets for Mild to Moderate Pain and Fever
Moore, N. D. (2007) · Clinical Drug Investigation · doi:10.2165/00044011-200727030-00002 · Cited by 64
Aspirin, NSAIDs, Risk of Dementia, and Influence of the Apolipoprotein E Epsilon 4 Allele in an Elderly Population
Cornelius, C., Fastbom, J., Winblad, B. G., & Viitanen, M. H. (2004) · Neuroepidemiology · doi:10.1159/000075957 · Cited by 66
Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Würtz, M., & Grove, E. L. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803251925 · Cited by 65
Clinical pharmacology of antiplatelet drugs
Gelbenegger, G., & Jilma, B. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2121702 · Cited by 63
Aspirin Resistance: Current Status and Role of Tailored Therapy
Grinstein, J., & Cannon, C. P. (2012) · Clinical Cardiology · doi:10.1002/clc.22031 · Cited by 64
Antiplatelet therapy in peripheral arterial disease. Consensus statement
Stansby, G. P., Mikhailidis, D., Flather, M., Smout, J., Beard, J., Bradbury, A., Bowbrick, V., Fowkes, G., Gent, M., Geroulakos, G., et al. (2003) · European Journal of Vascular and Endovascular Surgery · doi:10.1053/ejvs.2002.1927 · Cited by 63
Terms and Conditions
Hennekens, C. H., Schrör, K., Weisman, S. M., & FitzGerald, G. A. (2004) · Circulation · doi:10.1161/01.cir.0000142056.69970.db · Cited by 63
Self-citation
Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease
Patrignani, P. (2003) · Thrombosis Research · doi:10.1016/s0049-3848(03)00382-7 · Cited by 62
Pain management for dentists: the role of ibuprofen.
Pozzi, A., & Gallelli, L. (2011) · PubMed Central · Cited by 61
Do Aspirin and Other Antiplatelet Drugs Reduce the Mortality in Critically Ill Patients?
Lösche, W., Boettel, J., Kabisch, B., Winning, J., Claus, R. A., & Bauer, M. W. (2011) · Thrombosis · doi:10.1155/2012/720254 · Cited by 61
NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease
Kohli, P., Steg, P. G., Cannon, C. P., Smith, S. C., Eagle, K. A., Ohman, E. M., Alberts, M. J., Hoffman, E., Guo, J., Simon, T., et al. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.08.017 · Cited by 60
Spider diagram and sustainability evaluation of UV-methods strategy for quantification of aspirin and sildenafil citrate in the presence of salicylic acid in their bulk and formulation
Kayali, Z., Obaydo, R. H., & Sakur, A. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15260 · Cited by 60
Postoperative naproxen after coronary artery bypass surgery: a double-blind randomized controlled trial
Kulik, A., Ruel, M., Bourke, M. C., SAWYER, L., Penning, J., Nathan, H. J., Mesana, T. G., & BEDARD, P. (2004) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2004.07.004 · Cited by 60

Authors: Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A.
Affiliations: University of Pennsylvania (US)
ORCID: Reilly, Muredach P.
Kapoor, Shiv C.
Cucchiara, Andrew J.
Tournier, Barbara
FitzGerald, Garret A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-12-20
Volume: 345
Issue: 25
Pages: 1809-1817
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa003199
OpenAlex: W2011327495
Cited by: 1,394
References: 44
Citations by year: 2026: 19 · 2025: 15 · 2024: 18 · 2023: 18 · 2022: 33 · 2021: 43 · 2020: 33 · 2019: 40 · 2018: 40 · 2017: 46 · 2016: 41 · 2015: 56 · 2014: 46 · 2013: 69 · 2012: 79
FWCI: 50.64
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: National Heart, Lung, and Blood Institute (HL 5400, HL62250, P01HL062250)
National Center for Research Resources (M01-RR-00040, M01RR000040)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords: aspirin, ibuprofen, cyclooxygenase inhibitors, rofecoxib, diclofenac, paracetamol, drug interactions, platelet aggregation, thromboxane B2, antiplatelet activity, nonsteroidal anti-inflammatory drugs, arthritis treatment, cardiovascular risk, cardioprotection
MeSH terms: Acetaminophen, Adult, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Diclofenac, Drug Interactions, Drug Therapy, Combination, Humans, Ibuprofen, Isoenzymes, Lactones, Membrane Proteins, Middle Aged, Platelet Aggregation, Platelet Aggregation Inhibitors, Prostaglandin-Endoperoxide Synthases, Sulfones, Thromboxane B2, Dinoprostone, Cyclooxygenase Inhibitors, Cross-Over Studies, Analgesics, Non-Narcotic, Cyclooxygenase 1, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks